A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

B. J. Eigl; S. North; E. Winquist; D. Finch; L. Wood; S. S. Sridhar; J. Powers; J. Good; M. Sharma; J. A. Squire; J. Bazov; T. Jamaspishvili; M. E. Cox; P. A. Bradbury; E. A. Eisenhauer; K. N. Chi

doi:10.1007/s10637-015-0252-4

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

B. J. Eigl, S. North, E. Winquist, D. Finch, L. Wood, S. S. Sridhar, J. Powers, J. Good, M. Sharma, J. A. Squire, J. Bazov, T. Jamaspishvili, M. E. Cox, P. A. Bradbury, E. A. Eisenhauer, K. N. Chi

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Original language	English
Pages (from-to)	969-976
Number of pages	8
Journal	Investigational New Drugs
Volume	33
Issue number	4
DOIs	https://doi.org/10.1007/s10637-015-0252-4
Publication status	Published - Aug 2015
Externally published	Yes

ASJC Scopus Subject Areas

Pharmacology (medical)
Oncology
Pharmacology

Keywords

Castration resistant prostate cancer
HDAC
Histone deacetylase inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-015-0252-4

Cite this

Eigl, B. J., North, S., Winquist, E., Finch, D., Wood, L., Sridhar, S. S., Powers, J., Good, J., Sharma, M., Squire, J. A., Bazov, J., Jamaspishvili, T., Cox, M. E., Bradbury, P. A., Eisenhauer, E. A., & Chi, K. N. (2015). A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs, 33(4), 969-976. https://doi.org/10.1007/s10637-015-0252-4

Eigl, BJ, North, S, Winquist, E, Finch, D, Wood, L, Sridhar, SS, Powers, J, Good, J, Sharma, M, Squire, JA, Bazov, J, Jamaspishvili, T, Cox, ME, Bradbury, PA, Eisenhauer, EA & Chi, KN 2015, 'A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195', Investigational New Drugs, vol. 33, no. 4, pp. 969-976. https://doi.org/10.1007/s10637-015-0252-4

@article{1e5a001010b34a2b992b3c53b0564757,

title = "A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195",

keywords = "Castration resistant prostate cancer, HDAC, Histone deacetylase inhibitors",

author = "Eigl, {B. J.} and S. North and E. Winquist and D. Finch and L. Wood and Sridhar, {S. S.} and J. Powers and J. Good and M. Sharma and Squire, {J. A.} and J. Bazov and T. Jamaspishvili and Cox, {M. E.} and Bradbury, {P. A.} and Eisenhauer, {E. A.} and Chi, {K. N.}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York 2015.",

year = "2015",

month = aug,

doi = "10.1007/s10637-015-0252-4",

language = "English",

volume = "33",

pages = "969--976",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer

T2 - NCIC clinical trials group study IND195

AU - Eigl, B. J.

AU - North, S.

AU - Winquist, E.

AU - Finch, D.

AU - Wood, L.

AU - Sridhar, S. S.

AU - Powers, J.

AU - Good, J.

AU - Sharma, M.

AU - Squire, J. A.

AU - Bazov, J.

AU - Jamaspishvili, T.

AU - Cox, M. E.

AU - Bradbury, P. A.

AU - Eisenhauer, E. A.

AU - Chi, K. N.

PY - 2015/8

Y1 - 2015/8

KW - Castration resistant prostate cancer

KW - HDAC

KW - Histone deacetylase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84944441620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944441620&partnerID=8YFLogxK

U2 - 10.1007/s10637-015-0252-4

DO - 10.1007/s10637-015-0252-4

M3 - Article

C2 - 25983041

AN - SCOPUS:84944441620

SN - 0167-6997

VL - 33

SP - 969

EP - 976

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this